Not recruiting

Study Comparing Ribociclib and Palbociclib for Patients with Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Fast replyRegistered drugNo placebo

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying treatments for advanced hormone receptor-positive/HER2-negative/HER2-Enriched breast cancer. The study will compare two medications: ribociclib (also known as LEE011) and palbociclib, both of which are used in combination with endocrine therapy. The purpose of the study is to see which treatment is more effective in delaying the progression of the disease.

Participants in the study will receive either ribociclib or palbociclib, along with standard endocrine therapy. Ribociclib is taken as a film-coated tablet, while palbociclib is available in hard capsule form. The study will also include a group receiving a placebo. The trial will monitor the participants over a period to assess how well the treatments work in controlling the cancer and improving the quality of life for patients.

The study will involve regular visits to the clinic for treatment and monitoring. Participants will undergo various tests to track the progress of their condition and the effects of the treatment. The trial aims to provide valuable information on the safety and effectiveness of these medications in treating this specific type of breast cancer.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

Step 1
Joining the study
Upon joining the study, the patient will be required to provide signed informed consent. This is necessary before any trial-specific procedures can begin.
A molecular pre-screening consent must also be signed prior to the PAM50 test, which is used to analyze the tumor subtype.
Step 2
Initial assessments
The patient will undergo various assessments to ensure eligibility, including blood tests to check hematologic and organ function.
A pregnancy test is required for women of childbearing potential, and effective contraception must be used during the trial.
Step 3
Treatment allocation
The patient will be randomly assigned to one of two treatment groups: ribociclib plus endocrine therapy or palbociclib plus endocrine therapy.
Both medications are used to treat advanced hormone receptor-positive, HER2-negative breast cancer.
Step 4
Medication administration
If assigned to the ribociclib group, the patient will take Kisqali 200 mg film-coated tablets orally.
If assigned to the palbociclib group, the patient will take IBRANCE hard capsules orally, with available dosages of 75 mg, 100 mg, or 125 mg.
Step 5
Additional treatments
Patients may also receive Tevimbra 100 mg concentrate for solution for infusion intravenously, depending on the specific treatment plan.
The frequency and duration of these treatments will be determined by the study protocol.
Step 6
Ongoing assessments
Throughout the trial, regular assessments will be conducted to monitor the patient's health and response to treatment.
These assessments may include physical exams, blood tests, and imaging studies.
Step 7
End of treatment
The trial is expected to continue until July 2028, with the duration of individual participation varying based on treatment response and other factors.
Upon completion of the trial, final assessments will be conducted to evaluate the patient's condition.

Who can join the trial?

18 criteria

Patients must have advanced breast cancer that is **hormone receptor-positive** and **HER2-negative**.
Patients must sign an informed consent form before any trial-specific procedures begin.
Patients need to have adequate blood and organ function, as shown by specific lab tests.
Patients must be willing and able to follow the trial's schedule, including visits, treatments, and tests.
Women who can become pregnant must have a negative pregnancy test before starting the trial.
Women who can become pregnant must agree to use highly effective birth control methods during the trial and for a period after stopping treatment.
Postmenopausal women or those who meet specific criteria can participate. Pre/perimenopausal women can join if they agree to additional treatment with specific medications.
Patients must be able to swallow pills.
Patients need to have a normal heart rhythm and heart rate as shown by an **ECG** test.
Men who are not sterile must use effective birth control during the study and for at least 120 days after the last dose of the study medication.
Participants must be at least 18 years old.
Patients must have breast cancer confirmed by specific tests showing it is **hormone receptor-positive** and **HER2-negative**.
Patients must have a good performance status, meaning they can carry out daily activities without significant limitations.
Previous radiation therapy for cancer that has spread is allowed if the patient has recovered from any side effects.
Patients must have advanced breast cancer that is not treatable with curative therapy or has spread to other parts of the body.
Patients must provide a tumor sample for specific testing to determine eligibility.
Patients must have a specific subtype of breast cancer as determined by a central test.
Patients must have measurable or evaluable disease according to specific criteria.

Who cannot join the trial?

4 criteria

Patients who do not have advanced **hormone receptor-positive**/**HER2-negative**/**HER2-Enriched** breast cancer. This means the cancer must be of a specific type that responds to hormones and is not related to a protein called HER2.
Patients who are not within the specified age range for the study. The study may have specific age requirements.
Patients who are not female or male, as the study includes both genders.
Patients who are considered part of a **vulnerable population**. This term refers to groups of people who might be at a higher risk of harm or exploitation, such as children, pregnant women, or those with certain disabilities.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Verified
Fundacion Instituto Valenciano De Oncologia
Valencia, Spain
Verified
Hospital Clinic De Barcelona
Barcelona, Spain
Responsive
Hospital Universitario Hm Sanchinarro
Madrid, Spain

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting

Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Ribociclib
is a medication used in this trial to treat advanced breast cancer that is hormone receptor-positive and HER2-negative. It works by inhibiting certain proteins in cancer cells, which can slow down or stop the growth of the cancer.
Palbociclib
is another medication used in the trial for the same type of breast cancer. Like ribociclib, it targets specific proteins in cancer cells to help control the progression of the disease.
Endocrine Therapy
is a treatment that involves using hormone-blocking medications to slow or stop the growth of hormone receptor-positive breast cancer. This therapy is used in combination with either ribociclib or palbociclib in the trial.

What is already known about the treatment

Ribociclib
Ribociclib is administered orally in tablet form. It is currently being studied in clinical trials for its effectiveness in treating advanced hormone receptor-positive, HER2-negative, and HER2-Enriched breast cancer. The medication works by inhibiting certain proteins called cyclin-dependent kinases, which are involved in cell division, thereby slowing down the growth of cancer cells. Ribociclib is classified as a CDK4/6 inhibitor.
Palbociclib
Palbociclib is also taken orally as a tablet. It is being compared to ribociclib in clinical trials for its use in treating advanced hormone receptor-positive, HER2-negative, and HER2-Enriched breast cancer. Like ribociclib, palbociclib targets cyclin-dependent kinases to prevent cancer cell proliferation. It belongs to the same pharmacological class as ribociclib, known as CDK4/6 inhibitors.

Investigated diseases

Advanced Hormone Receptor-Positive/HER2-Negative/HER2-Enriched Breast Cancer – This type of breast cancer is characterized by the presence of hormone receptors, meaning the cancer cells grow in response to hormones like estrogen or progesterone. It is negative for the human epidermal growth factor receptor 2 (HER2), which means it does not overexpress the HER2 protein. The HER2-enriched subtype is a specific category within this group, known for its unique gene expression profile. This cancer can progress by spreading to other parts of the body, often affecting bones, liver, lungs, or brain. The progression is typically monitored through imaging and clinical assessments to evaluate changes in tumor size and spread. The disease's behavior can vary, with some cases showing slow progression while others may advance more rapidly.